| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.08T | 1.13T | 1.16T | 1.13T | 911.43B | 863.38B |
| Gross Profit | 461.77B | 479.42B | 504.68B | 485.94B | 392.74B | 374.65B |
| EBITDA | 33.68B | -60.74B | 106.18B | -16.80B | 60.35B | 66.32B |
| Net Income | -13.01B | -47.85B | 4.52B | -103.15B | -26.12B | -15.21B |
Balance Sheet | ||||||
| Total Assets | 1.22T | 1.22T | 1.39T | 1.41T | 1.34T | 1.30T |
| Cash, Cash Equivalents and Short-Term Investments | 103.53B | 89.90B | 127.13B | 183.06B | 117.67B | 123.82B |
| Total Debt | 463.86B | 438.17B | 522.58B | 568.29B | 448.65B | 410.70B |
| Total Liabilities | 690.64B | 743.56B | 834.67B | 913.90B | 776.62B | 749.05B |
| Stockholders Equity | 519.65B | 463.15B | 539.82B | 487.42B | 549.81B | 539.89B |
Cash Flow | ||||||
| Free Cash Flow | 23.38B | 25.30B | 38.21B | -27.46B | -23.61B | 37.86B |
| Operating Cash Flow | 67.26B | 51.09B | 83.34B | 13.32B | 37.44B | 78.06B |
| Investing Cash Flow | 26.66B | 24.65B | -44.53B | -37.50B | -51.00B | -34.33B |
| Financing Cash Flow | -101.47B | -110.90B | -96.85B | 84.32B | 2.13B | -13.09B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ¥803.55B | 14.15 | 7.77% | 3.16% | 4.30% | 78.29% | |
73 Outperform | ¥753.22B | 18.01 | 10.63% | 2.03% | 5.40% | 23.70% | |
71 Outperform | ¥820.06B | 12.67 | 5.91% | 2.78% | 4.46% | 70.22% | |
66 Neutral | ¥34.70B | 79.60 | ― | 4.37% | 0.33% | -65.09% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
58 Neutral | ¥3.60T | 13.22 | 7.92% | 2.07% | 5.39% | 12.69% | |
47 Neutral | ¥293.09B | -23.42 | -12.69% | 0.71% | -11.22% | -731.07% |
Konica Minolta reported a return to solid profitability for the nine months ended December 31, 2025, despite a 6.1% year-on-year decline in revenue to ¥781.1 billion, reflecting the exclusion of its Precision Medicine Business, now classified as a discontinued operation. Business contribution profit rose 20.5% to ¥34.7 billion and operating profit swung from a loss of ¥18.5 billion in the prior-year period to a profit of ¥33.3 billion, while profit attributable to owners reached ¥21.4 billion, translating into basic earnings per share of ¥43.38 versus a loss per share a year earlier. The company’s financial position also strengthened, with equity attributable to owners increasing to ¥519.7 billion and the equity ratio improving to 42.5% from 38.0% at the March 2025 year-end, and Konica Minolta reinstated shareholder returns via an interim dividend of ¥5 per share and a full-year dividend forecast of ¥10 per share, signaling confidence in its earnings recovery and balance sheet health.
The most recent analyst rating on (JP:4902) stock is a Hold with a Yen620.00 price target. To see the full list of analyst forecasts on Konica Minolta stock, see the JP:4902 Stock Forecast page.